Covid-19 Diagnostics Market to Scale New Heights, Anticipating US$204.51 Billion by 2032
The COVID-19 Diagnostics Market is positioned for exceptional growth, projecting a substantial climb to surpass the valuation of US$ 204.51 billion by 2032, driven by an impressive compound annual growth rate (CAGR) of 7.7%. This anticipated surge reflects the crucial role of diagnostic tools in managing the ongoing pandemic. As global efforts continue to combat COVID-19, this market’s exponential expansion underscores the significance of accurate and efficient testing solutions. The trajectory not only demonstrates the resilience of the healthcare sector but also the industry’s commitment to advancing diagnostic technologies in the face of unprecedented challenges.
The report features unique and salient factors that may make a huge impact on the development of the Covid-19 Diagnostics Market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the market in the years to come. The report provides detailed information about the current and future growth prospects of the market in the most comprehensive way for better understanding of readers.
Key Segments of Covid-19 Diagnostics Market
FMI’s study on the market offers information divided into four important segments— Drug Class, Route of Administration, Application, and Region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Key Takeaways from FMI’s Covid-19 Diagnostics Market Study
• Molecular assay holds the largest share right now and the trend is expected to continue till the end of 2020. This could be attributed to the fact that molecular assays have been looked upon as a gold standard to detect novel viral infections
• Diagnostic labs contributed to more than 60% of total market share in 2020’s first quarter
Key Challenges for Market Players & Researchers
Right now, the challenges faced include lack of information regarding the virus, like genetic information, biologics, duration of immunity in the recovered patients.
Certain treatment options that are expected to be potential game changers include ACE-Mab by Sorrento Therapeutics, HCQ (Hydroxychloroquine and chloroquine), Remdesivir antiviral by Gilead Sciences, and Canakinumab (Ilaris) by Novartis.
Moreover, options like cell-based therapies that involve natural killer cells or Mesenchymal stem cells and plasma therapies are on the verge of providing personalized treatment options.
Key Participant Insights
The key participants are focusing on acceleration of production as well as new product approval phase. For example – Novacyt Group, in Mar 2020, received EUA for 2-hour Covid-19 test. Also, in Apr 2020, CE approval was received by Abbott for IgG serology blood test for Covid-19.
The other players in the market include Veredus Laboratories, Thermo Fisher Scientific, Inc., Quidel Corporation, Perkin Elmer, Inc., Neuberg Diagnostics, Mylab Discovery Solutions Pvt Ltd., Luminex Corporation, Laboratory Corporation of America Holdings, Hologic Inc., Danaher, Cepheid, bioMérieux SA, Altona Diagnostics GmbH, ALDATU BIOSCIENCES, ADT Biotech Sdn Bhd, and 1drop Inc.
Key Segment
Product Type
• Instruments
• Test Kits
• Reagents and Consumables
Sample Type
• Oropharyngeal & Nasopharyngeal Swabs
• Blood
• Urine
• Others
Technology
• PCR
• ELISA
• POC
Region
• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa
1 (877) 773-1002